<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118337</url>
  </required_header>
  <id_info>
    <org_study_id>D6020C00001</org_study_id>
    <nct_id>NCT02118337</nct_id>
  </id_info>
  <brief_title>A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of MEDI0680 (AMP-514) given in combination with
      MEDI4736.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acceptable number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>From first dose of study drugs until 90 days after the last dose of study drugs</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determination of maximum tolerated dose (MTD) to be assessed by number of AEs and SAEs, laboratory evaluations, vital signs, physical examinations, and electrocardiogram results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of MEDI0680 (AMP-514) in combination with MEDI4736 in subjects with advanced malignancies</measure>
    <time_frame>From first dose of study drugs until end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by OR, DC, DoR, PFS and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI0680 (AMP-514) and MEDI4736</measure>
    <time_frame>From first dose through 12 months after last dose of study drugs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Individual concentrations in serum including peak and trough concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MEDI0680 (AMP-514) and MEDI4736</measure>
    <time_frame>From first dose of study drugs until 90 days after last dose of study drugs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity measured by presence of detectable ADAs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum sPD-L1 Levels</measure>
    <time_frame>From first dose of study drugs until 90 days after last dose of study drugs</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess drug exposure and response to treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-1 expression/MEDI0680 (AMP-514) receptor occupancy</measure>
    <time_frame>From first dose of study drugs until end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess drug exposure and response to treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Flow Cytometry levels</measure>
    <time_frame>From first dose of study drugs through the last dose of study drugs</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess cell populations with drug exposure and response to treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Circulating Soluble Factor levels</measure>
    <time_frame>From first dose of study drugs until 90 days after last dose of study drugs</time_frame>
    <safety_issue>No</safety_issue>
    <description>to assess pre and post treatment levels with response to treatment with study drugs</description>
  </other_outcome>
  <other_outcome>
    <measure>Expression of biomarkers within the tumor microenvironment</measure>
    <time_frame>From first dose of study drugs until end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the molecules and biomarkers present in the tumor microenvironment pre and post dose</description>
  </other_outcome>
  <other_outcome>
    <measure>miRNA/mRNA levels in the blood</measure>
    <time_frame>From first dose of study drugs through end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>to determine changes in gene expression from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Biopsy specimen results</measure>
    <time_frame>From screening through end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the genetic profile of the tumor in relation to response or resistance</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor Response</measure>
    <time_frame>From screening through end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor response will be assessed by irRECIST</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>From screening through end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed through questionnaires regarding quality of life, symptoms, pain, and health status</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation of MEDI0680 (AMP-514) and MEDI4736 in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Expansion at selected dose from escalation phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI0680 (AMP-514):  MEDI0680 and AMP-514 are interchangable nomenclature</intervention_name>
    <description>anti-PD-1</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>anti-PD-L1</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years or older

          -  Eastern Cooperative Oncology Group performance status of 0-1

          -  Adequate organ function

        Exclusion Criteria:

          -  Concurrent enrollment in another clinical study, unless in follow-up period or it is
             an observational study

          -  Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
             treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyson Karakunnel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MedImmune Contact</last_name>
    <email>ClinicalTrialEnquiries@Medimmune.com</email>
  </overall_contact>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced malignancies</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
